Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellcarcinomacardiaccancercreatinine
  Phrases that lowered it: bodyweekspatients whoreceivedtreatment
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 52.3% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 6.2% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor's past trials: 2 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma NCT01144169 · started 2010 · scored riskier than 59% of active trials terminated
• Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy NCT00813423 · started 2010 · scored riskier than 24% of active trials completed
• A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer NCT02960906 · started 2017 · scored riskier than 90% of active trials completed
• Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma NCT03274258 · started 2018 · scored riskier than 75% of active trials terminated
• Immunotherapy Study for Metastatic Renal Cell Cancer NCT02035358 · started 2015 · scored riskier than 89% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.